Second Sight Announces Successful Implantation and Activation of Wireless Visual Cortical Stimulator in First Human Subject

SYLMAR, Calif.--- Second Sight Medical Products, Inc. (EYES) (Second Sight or the Company), a developer, manufacturer and marketer of implantable visual prosthetics to restore functional vision to blind patients, today announced the first successful implantation and activation of a wireless visual cortical stimulator in a human subject, providing the initial human proof of concept for the ongoing development of the Company’s Orion™ I Visual Cortical Prosthesis (Orion I). In the UCLA study supported by Second Sight, a 30 year old patient was implanted with a wireless multichannel neurostimulation system on the visual cortex and was able to perceive and localize individual phosphenes or spots of light with no significant adverse side effects.
Dr. Robert Greenberg, Chairman of the Board of Second Sight, said, “It is rare that technological development offers such stirring possibilities. This first human test confirms that we are on the right track with our Orion I program to treat blind patients who cannot benefit from the Argus® II Retinal Prosthesis (Argus II). 
Read more: Second Sight Medical Products ( EYES )

ICTV Brands, Inc. Announces Definitive Agreement to Acquire the no!no! Hair Removal Brand

WAYNE, PA--(Oct 5, 2016) - ICTV Brands, Inc. (ICTV), ( CSE : ITV ), a digitally focused, direct response marketing and branding company specializing in the health, wellness and beauty sector, today announced the signing of a definitive agreement to acquire the consumer products business of PhotoMedex, Inc. ( NASDAQ :PHMD ) for a total consideration of $9.5 million.
The agreement calls for ICTV to acquire the assets of PhotoMedex's flagship product no!no!, along with the Kyrobak and Cleartouch brands. The purchase price of $9.5 million consists of a $3 million cash payment on closing, $2 million cash payment due on the 90th day following the closing, and a $4.5 million capped royalty based on future net sales of the acquired product lines. This asset purchase will include the respective product trademarks, patents, and other intellectual property, along with manufacturing tooling, and PhotoMedex's Hong Kong and Brazilian subsidiaries. ICTV will also receive a minimum of $6 million of GAAP inventory.
Read more: PhotoMedex Inc ( PHMD )

Cogentix Medical Enters Into Definitive Agreement For $25 Million Equity Investment

MINNEAPOLIS, Sept. 7, 2016  -- Cogentix Medical, Inc. (CGNT), a medical device company that develops, manufactures and markets innovative proprietary products for the urology market, today announced that it has entered into a securities purchase agreement with Accelmed Growth Partners, L.P.  Under the terms of the securities purchase agreement, Accelmed would purchase $25 million of Cogentix Medical common stock from the Company at $1.55 per share, a 29% premium over the closing price of the stock on September 6, 2016 and a premium of 36% over the average closing price over the last 30 days.  The securities purchase agreement is subject to various closing conditions, including approval by the shareholders of Cogentix Medical.  Accelmed is a premier capital resource for the medical device industry and is based in New York, NY and Hertzeliya, Israel.  Cogentix would apply the proceeds to working capital as well as the implementation of a business development strategy to acquire growth technologies addressing the urology market.
Read more: Cogentix Medical Inc ( CGNT )

Boston Scientific to Acquire EndoChoice

MARLBOROUGH, Mass. and ALPHARETTA, Ga., Sept. 27, 2016  -- Boston Scientific (BSX) and EndoChoice Holdings, Inc. (GI) today announced the companies have entered into a definitive agreement under which Boston Scientific has agreed to acquire EndoChoice. Upon completion of the transaction, EndoChoice will become part of the Boston Scientific endoscopy business.
EndoChoice develops and commercializes innovative products and services for specialists treating a wide range of gastrointestinal (GI) conditions. The EndoChoice portfolio includes single-use devices, such as resection and retrieval devices, needles, graspers and infection control kits. The company also has strong positions in pathology services and imaging technologies. 
Read more: EndoChoice Holdings Inc ( GI )

Aethlon Medical Announces Zika Virus Data

SAN DIEGO, Aug. 11, 2016  -- Aethlon Medical, Inc. (AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, announced today that its researchers have completed in vitro studies that demonstrate the rapid capture of Zika virus by the Aethlon Hemopurifier®. The Hemopurifier® is a leading broad-spectrum treatment countermeasure against viral pathogens that are untreatable with or resistant to antiviral drug therapies.  At present, the immunotherapeutic technology is being advanced through an FDA approved human feasibility study.  The Zika studies, which were conducted with small-scale versions of the Hemopurifier®, demonstrated a 95% clearance of Zika virus from cell culture fluid in 5.5 hours and an approximate 50% clearance of Zika from human blood serum in 5 hours. 
The studies were conducted with the Zika viral strain that has recently spread from South America to ravage Puerto Rico and likely responsible for the first wave of infections that have begun to occur in the United States.  
Read more: Aethlon Medical Inc ( AEMD )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker